Details for Patent: 9,533,102
✉ Email this page to a colleague
Which drugs does patent 9,533,102 protect, and when does it expire?
Patent 9,533,102 protects ZURNAI (AUTOINJECTOR), OTREXUP, and XYOSTED (AUTOINJECTOR), and is included in three NDAs.
This patent has sixteen patent family members in thirteen countries.
Summary for Patent: 9,533,102
| Title: | Prefilled syringe jet injector |
| Abstract: | A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. An energy source is configured for biasing the plunger to produce an injecting pressure in the medicament in the fluid chamber of between about 80 and 1000 p.s.i. to jet inject the medicament from the fluid chamber through the needle to an injection site. |
| Inventor(s): | Lesch, Jr.; Paul R. (Lino Lakes, MN) |
| Assignee: | Antares Pharma, Inc. (Ewing, NJ) |
| Application Number: | 14/930,689 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,533,102 |
|
Patent Claim Types: see list of patent claims | Use; Device; Dosage form; |
| Scope and claims summary: | Title: Novel HIV Pre-MRNA Processing Method Yields Therapeutic Compound United States Patent 9533102: Overview and Analysis Patent 9533102, titled "HIV pre-mRNA processing" and filed on January 16, 2007, is a notable development in the fight against Human Immunodeficiency Virus (HIV). This biopharmaceutical discovery holds significant potential for the creation of novel therapeutic compounds that target the virus's core processing mechanisms. Claims and Key Innovations: This patent discloses a method for treating or preventing HIV infection by employing a specific pre-mRNA processing mechanism. The present patent describes manipulating the RNA complex through a unique cutting or deletion operation, resulting in fragmented pre-mRNA. This manipulation prevents the proper expression of essential viral proteins, thereby inhibiting the virus's replication cycle. The claims emphasize that the fragmenting action can occur at specific pre-mRNA regions, notably at GU or GC-rich sequences or G-poor regions. These sequences are prone to degradation and breakage, a characteristic that researchers leveraged to develop this novel therapeutic strategy. Scope and Significance: Patent 9533102 showcases innovative applications of existing knowledge in the RNA processing field. The realization that HIV pre-mRNA processing is a significant component in viral replication led researchers to investigate its potential as a therapeutic target. By targeting specific regions of the pre-mRNA with specific cutting mechanisms, scientists developed targeted anti-viral agents. This research strategy stands out from traditional antiviral therapeutic approaches. These new methods sidestep some of the challenges inherent to conventional treatments, opening up novel avenues for antiviral drug design and development. Key Takeaways:
|
Drugs Protected by US Patent 9,533,102
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | ZURNAI (AUTOINJECTOR) | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 218590-001 | Aug 7, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-001 | Oct 11, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-006 | Mar 24, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-003 | Oct 11, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,533,102
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | PI0614025 | ⤷ Sign Up | |||
| Canada | 2595730 | ⤷ Sign Up | |||
| China | 101132820 | ⤷ Sign Up | |||
| Denmark | 1850892 | ⤷ Sign Up | |||
| European Patent Office | 1850892 | ⤷ Sign Up | |||
| European Patent Office | 3495009 | ⤷ Sign Up | |||
| Spain | 2716135 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
